CSCindy L. Schwartz

Cindy L. Schwartz

*This is an algorithmically generated author record based on publicly available information.

Cindy L. Schwartz has a total of 38 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Childhood Hodgkin International Prognostic Score (CHIPS) Predicts event-free survival in Hodgkin Lymphoma: A Report from the Children's Oncology Group

    by Cindy L. Schwartz, Lu Chen, Kathleen McCarten, Suzanne Wolden, Louis S. Constine, Robert E. Hutchison, Pedro A. de Alarcon, Frank G. Keller, Kara M. Kelly, Tanya A. Trippet, et al.

    Background Early response to initial chemotherapy in Hodgkin lymphoma (HL) measured by computed tomography (CT) and/or positron emission tomography (PET) after two to three cycles of chemotherapy may inform therapeutic decisions. Risk stratification at diagnosis could, however, allow earlier and potentially more efficacious treatment modifications. Patients and Methods We developed a predictive model for event‐free survival (EFS) in pediatric/adolescent HL using clinical data known at diagnosis from 1103 intermediate‐risk HL patients treated on Children's Oncology Group protocol AHOD0031 with doxorubicin, bleomycin, vincristine, etoposide, prednisone, cyclophosphamide (ABVE‐PC) chemotherapy and radiation. Independent predictors of EFS were identified and used to develop and validate a prognostic score (Childhood Hodgkin International Prognostic Score [CHIPS]). A training cohort was randomly selected to include approximately half of the overall cohort, with the remainder forming the validation cohort. Results Stage 4 disease, large mediastinal mass, albumin (<3.5), and fever were independent predictors of EFS that were each assigned one point in the CHIPS. Four‐year EFS was 93.1% for patients with CHIPS = 0, 88.5% for patients with CHIPS = 1, 77.6% for patients with CHIPS = 2, and 69.2% for patients with CHIPS = 3. Conclusions CHIPS was highly predictive of EFS, identifying a subset (with CHIPS 2 or 3) that comprises 27% of intermediate‐risk patients who have a 4‐year EFS of <80% and who may benefit from early therapeutic augmentation. Furthermore, CHIPS identified higher risk patients who were not identified by early PET or CT response. CHIPS is a robust and inexpensive approach to predicting risk in patients with intermediate‐risk HL that may improve ability to tailor therapy to risk factors known at diagnosis.


  • Pharmacogenomic prediction of treatment-induced severe lung toxicity in Hodgkin lymphoma (HL).

    by Rebekah Karns, Mayur Sarangdhar, Bruce Aronow, Mitali Basu, Cindy L. Schwartz, Kara M. Kelly, Debra L. Friedman, John Peter Perentesis

    7522 Background: Contemporary therapies produce high cure rates in HL. However, complications of treatment produce substantial morbidity and mortality. Identification of individuals at high risk for toxicity is a goal for precision HL therapy. Methods: We conducted a nested case-control study of 953 intermediate risk HL patients enrolled on the Childrens Oncology Group AHOD0031 protocol, assessing associations between severe lung toxicity and clinical, demographic, & genetic predictors. Chemotherapy included doxorubicin, bleomycin, vincristine, etoposide, cyclophosphamide, and prednisone. The frequency of 1936 variant alleles (1931 SNPs & 5 CNVs) in 225 drug metabolism enzyme and transporter genes were compared between patients with no/mild (n=929) & severe (n=24) lung toxicities. Significant polymorphisms (pNAT2, SLCO1B1 & ABCC1. Risk alleles were summed across the 3 polymorphisms, generating an allelic risk score ranging from 0-5. A regression model for prediction of lung toxicity included allelic risk score and erythrocyte sedimentation rate (ESR). The model identified a high-risk group with severe lung toxicity prevalence of >9%, and a low-risk group with prevalence of 1.5%. Within the high-risk subset, a second-stage test of polymorphisms in GSTA4 and SLCO1B1 identified a subset with a prevalence of >28%. Within the low-risk subset, polymorphisms in CYP11B1, SLC7A8, and SLCO1B1 identified individuals with a prevalence of >8%. To validate the results, we retested the model in 1000 bootstrapped data sets generated from the original data. Conclusions: A two-step algorithm combining genetic risk alleles in 8 polymorphisms, integrated with ESR, identifies HL patients at low (28%) risk for severe pulmonary toxicities. These results suggest potential for genomic-guided therapy regimen assignment to avoid drugs (eg bleomycin) associated with lung toxicity in high risk patients. This work serves as a model for approaches to other HL toxicities.

  • Intensified Chemotherapy With Dexrazoxane Cardioprotection in Newly Diagnosed Nonmetastatic Osteosarcoma: A Report From the Children's Oncology Group

    by Cindy L. Schwartz, Leonard H. Wexler, Mark D. Krailo, Lisa A. Teot, Meenakshi Devidas, Laurel J. Steinherz, Allen M. Goorin, Mark C. Gebhardt, John H. Healey, Judith K. Sato, et al.

    Background: Although chemotherapy has improved outcome of osteosarcoma, 30–40% of patients succumb to this disease. Survivors experience substantial morbidity and mortality from anthracycline‐induced cardiotoxicity. We hypothesized that the cardioprotectant dexrazoxane would (i) support escalation of the cumulative doxorubicin dose (600 mg/m2) and (ii) not interfere with the cytotoxicity of chemotherapy measured by necrosis grading in comparison to historical control data.Procedure: Children and adolescents with nonmetastatic osteosarcoma were treated with MAP (methotrexate, doxorubicin, cisplatin) or MAPI (MAP/ifosfamide). Dexrazoxane was administered with all doxorubicin doses. Cardioprotection was assessed by measuring left ventricular fractional shortening. Interference with chemotherapy‐induced cytotoxicity was determined by measuring tumor necrosis after induction chemotherapy. Feasibility of intensifying therapy with either high cumulative‐dose doxorubicin or high‐dose ifosfamide/etoposide was evaluated for “standard responders” (SR, 2) and dexrazoxane, grade 1 or 2 left ventricular dysfunction occurred in five patients; 4/5 had transient effects. Left ventricular fractional shortening z‐scores (FSZ) showed minimal reductions (0.0170 ± 0.009/week) over 78 weeks. Two patients (<1%) had secondary leukemia, one as a first event, a similar rate to what has been observed in prior trials. Intensification with high‐dose ifosfamide/etoposide was also feasible.Conclusions: Dexrazoxane cardioprotection was safely administered. It did not impair tumor response or increase the risk of secondary malignancy. Dexrazoxane allowed for therapeutic intensification increasing the cumulative doxorubicin dose in SR to induction chemotherapy. These findings support the use of dexrazoxane in children and adolescents with osteosarcoma. Pediatr Blood Cancer


  • The Thyroid Gland

    by Michael T. Milano, Sughosh Dhakal, Cindy L. Schwartz, Louis S. Constine

  • Facilitating Assessment of Late Effects by Organ System

    by Cindy L. Schwartz, Wendy L. Hobbie, Louis S. Constine

  • Pulmonary Effects of Antineoplastic Therapy

    by Sughosh Dhakal, Daniel Weiner, Cindy Schwartz, Louis S. Constine

    Pulmonary toxicity is common after cancer therapy and can result from all therapeutic modalities. The consequential decrease in lung function ranges in severity from subclinical to life-threatening or even fatal and can manifest in the acute setting or many years after completion of therapy. Radiation effects are due to direct insult to the pulmonary parenchyma and, for younger children, impaired thoracic musculoskeletal development. Radiation pneumonitis can occur in the acute/subacute setting, as well as fibrosis with comprised gas exchange as a late effect of direct lung irradiation; thoracic wall malformation can cause restriction of function as a chronic sequela. The pulmonary effects of cytotoxic drugs usually present as acute effects, but there is the potential for significant late morbidity and mortality. Of course, surgical interventions can also cause both acute and/or late pulmonary effects as well, depending on the specific procedure. Although treatment approaches for the management of pediatric cancers are continually adapted to provide optimal therapy while minimizing toxicities, to a varying degree all therapies have the potential for both acute and late pulmonary toxicity. Of note, the cumulative incidence of pulmonary complications rises with increasing time since diagnosis, which suggests that adult survivors of childhood cancer require lifelong monitoring and management of potential new-onset pulmonary morbidity as they age. Knowledge of cytotoxic therapies and an understanding of lung physiology and how it may be altered by therapy facilitate appropriate clinical care and monitoring of long-term survivors.


  • Pediatric Hodgkin Lymphoma

    by Georgina W. Hall, Cindy L. Schwartz, Stephen Daw, Louis S. Constine